Zacks Research Issues Optimistic Estimate for ENSC Earnings

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Analysts at Zacks Research upped their Q3 2026 earnings per share estimates for Ensysce Biosciences in a note issued to investors on Tuesday, July 14th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings per share of $0.09 for the quarter, up from their previous forecast of ($0.49). The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($1.53) per share. Zacks Research also issued estimates for Ensysce Biosciences’ Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($1.53) EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Ensysce Biosciences in a research note on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Ensysce Biosciences Stock Performance

ENSC stock opened at $0.28 on Friday. The stock has a market capitalization of $4.35 million, a PE ratio of -0.08 and a beta of 0.78. The company has a fifty day moving average of $0.29 and a 200-day moving average of $0.49. Ensysce Biosciences has a one year low of $0.23 and a one year high of $2.75.

Ensysce Biosciences (NASDAQ:ENSC) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.21. The company had revenue of $0.96 million for the quarter, compared to analysts’ expectations of $1.00 million. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. grew its stake in shares of Ensysce Biosciences by 100.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after purchasing an additional 75,000 shares in the last quarter. DRW Securities LLC raised its stake in shares of Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after purchasing an additional 29,336 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Ensysce Biosciences during the third quarter valued at about $34,000. Finally, Virtu Financial LLC acquired a new stake in Ensysce Biosciences in the third quarter worth about $34,000. Institutional investors and hedge funds own 5.63% of the company’s stock.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.